Cubist Pharmaceuticals Inc: (NASD: CBST)

$48.77

0.00 (0.00%)

Volume 601,565

May 14 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		48.53 - 49.41
	
		52wk Low - High
		36.73 - 49.86
	
		Previous Close
		48.77
	
		Avg. Volume
		797,982
	
		Industry
		MED-DRUGS
	
		Market Cap
		3.17 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.54
	
		PE (Forward)
		25.59
	
		Current Year Est.
		1.91
	
		Quarterly Earnings ESP 
		4.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		93 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/22/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            25.59
                        
                            PEG Ratio
                            0.84
                        
                            Current Year Est.
                            1.91
                        
                            Current Quarter Estimate
                            0.50
                        
                            Most Accurate Estimate
                            0.52
                        
                            Earnings ESP 
                            4.00%
                        
                            Next Earnings Report Date
                            07-18-2013
                        
                            EPS Last Year
                            2.08
                        
                            Expected Earnings Growth
                            30.60%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN, the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA.   
Full CBST Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CBST Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.50	0.50	1.91	2.48
Number of Estimates	14	15	13	13
Low Estimate	0.28	0.32	1.18	1.49
High Estimate	0.73	0.73	2.61	NA
Year Ago EPS	0.58	0.68	2.65	1.91
EPS Growth	-13.05%	-27.06%	-28.07%	30.27%

More CBST Estimates

Average Earnings Estimates for CBST

EPS Growth for CBST

Industry Analysis

Name	Symbol	Previous Close
CUBIST PHARM	CBST	48.77
CATALYST PHARMA	CPRX	0.94
JAZZ PHARMACEUT	JAZZ	58.69
SANTARUS INC	SNTS	20.39
USANA HLTH SCI	USNA	58.19
BIOCRYST PHARMA	BCRX	1.81
CELL THERAPEUT	CTIC	1.19
ELAN CP PLC ADR	ELN	11.61
INFINITY PHARMA	INFI	32.99
LANNETT INC	LCI	11.74

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Celgene Attains 52-Week High

May 14, 2013

NPS Pharma Incurs Narrower 1Q Loss

May 14, 2013

Setback for Endo Health on Opana ER

May 13, 2013

Earnings Beat at Warner Chilcott

May 13, 2013

Narrower-than-Expected Loss at MannKind

May 13, 2013

Wider-than-Expected Loss at Optimer

May 10, 2013

The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals

May 10, 2013

Good News for Cubist Pharmaceuticals

May 09, 2013

More CBST Zacks Commentary

Financials

EPS TTM	2.08
Sales	926
Net Income	127
Price/Earnings	23.45
Price/Book	3.12
Price/Cash Flow	11.48
Price/Sales	3.35

More CBST Financials

News

South African It Specialist Sees New Ways to Link Tech Projects - All Africa Global Media

May 14, 2013

Benzinga`s M&A Chatter for Monday May 13, 2013 - Benzinga

May 13, 2013

Shares of Cubist Pharmaceuticals Receive a Boost, Up 1.8% - Financial News Network Online - Market Movers

May 13, 2013

4 GARP Growers to Buy This Summer - TheStreet.com

May 10, 2013

Buyers Accumulate Shares of Cubist Pharmaceuticals, Up 1.3% - Financial News Network Online - Market Movers

May 10, 2013

Cubist's Late-Stage Antibiotic Candidate Gets FDA Fast Track Designation - Close-Up Media

May 10, 2013

The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals - Pr Newswire

May 10, 2013

Cubist Pharmaceuticals (CBST) Showing Bullish Technicals With Resistance At $47.81 - Freshbrewedmedia

May 9, 2013

See All News Stories on CBST

Broker Recommendations

Current ABR	2.08
ABR (Last Week)	2.08
# of recs in ABR	18
Average Target Price	51.47
Industry Rank by ABR	93 out of 265
Rank in Industry	5 out of 91

More CBST Broker Recommendations

Day Low - High	48.53 - 49.41
52wk Low - High	36.73 - 49.86
Previous Close	48.77
Avg. Volume	797,982
Industry	MED-DRUGS
Market Cap	3.17 B
Div - Yield	0.00 - 0.00
Beta	0.54
PE (Forward)	25.59
Current Year Est.	1.91
Quarterly Earnings ESP	4.00%

PE (Forward)	25.59
PEG Ratio	0.84
Current Year Est.	1.91
Current Quarter Estimate	0.50
Most Accurate Estimate	0.52
Earnings ESP	4.00%
Next Earnings Report Date	07-18-2013
EPS Last Year	2.08
Expected Earnings Growth	30.60%

Username: Password:

Remember me [?]

Cubist Pharmaceuticals Inc: (NASD: CBST)

$48.77

0.00 (0.00%)

Volume 601,565

May 14 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations